ALCHealthcare · Medical Instruments & SuppliesThe 26 Wall Street analysts covering Alcon AG hold a median 12-month price target of $86 — +25.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 69 of 100 as at 8 Sept 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Alcon AG on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (95): The share price has been relatively steady.
Momentum (26): The shares have been drifting down relative to others.
Size (7): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on ALC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +25.7% from it.
Of the 20 most recent actions, 3 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Aug 2026 | JP Morgan | Maintains | Neutral | $78 → $78 |
| 12 Aug 2026 | Mizuho | Maintains | Outperform | $80 → $85 |
| 11 Aug 2026 | BTIG | Reiterates | Buy | $82 |
| 11 Aug 2026 | Needham | Maintains | Buy | $95 → $98 |
| 15 July 2026 | Mizuho | Maintains | Outperform | — |
| 15 July 2026 | Mizuho | Maintains | Outperform | $85 → $80 |
| 8 May 2026 | Barclays | Maintains | Equal-Weight | — |
| 7 May 2026 | Baird | Maintains | Outperform | — |
| 7 May 2026 | Mizuho | Maintains | Outperform | — |
| 7 May 2026 | Wells Fargo | Maintains | Overweight | — |
| 6 May 2026 | BTIG | Maintains | Buy | — |
| 6 May 2026 | Needham | Maintains | Buy | — |
| 23 Mar 2026 | BTIG | Reiterates | Buy | — |
| 9 Mar 2026 | Stifel | Maintains | Hold | — |
| 26 Feb 2026 | Barclays | Maintains | Equal-Weight | — |
| 26 Feb 2026 | Needham | Maintains | Buy | — |
| 26 Feb 2026 | Wells Fargo | Upgrade | Overweight | — |
| 25 Feb 2026 | BTIG | Maintains | Buy | — |
| 9 Jan 2026 | Stifel | Downgrade | Hold | — |
| 11 Dec 2025 | B of A Securities | Downgrade | Underperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ALC appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 9 Sept 2026, Alcon AG returned −12.8% against +18.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 14% of US stocks
Cheaper than 41% of US stocks
Cheaper than 55% of US stocks
Cheaper than 22% of US stocks
Higher than 48% of US stocks
Higher than 1% of US stocks
Higher than 73% of US stocks
Higher than 72% of US stocks
Higher than 62% of US stocks
Higher than 50% of US stocks
Higher than 64% of US stocks
Higher than 47% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Alcon AG has a market value of $34.1B and an enterprise value of $37.9B.
Revenue in the twelve months to 30 June 2026: $10.9B. The latest quarter grew 8.7% year on year.
Net income over the same four quarters: $643.0M, a 5.9% net margin.
Diluted earnings per share, trailing twelve months: $1.31.
Free cash flow in the twelve months to 30 June 2026: $1.6B.
Alcon AG spent $913.0M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 52.7×; forward P/E: 17.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 2.07%, paying out 27% of earnings.
Alcon AG employs 25,000 people — $434K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Alcon AG — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research published an analysis of Alcon (ALC), noting that its acquisitions, partnerships, and new product launches support growth while tariffs and intense competition remain key risks.
Why it matters — ALC watchers would care because the report weighs Alcon's growth drivers against its competitive and tariff-related risks in assessing its current outlook.
Seeking Alpha describes Alcon as a structurally advantaged ophthalmology leader with a durable equipment-to-consumables model and strong recurring revenue streams. The article notes the stock trades at about 18x forward earnings, with management targeting 25% core operating margin by FY2027 and raising core EPS growth guidance to 12–15%.
Why it matters — ALC watchers would care because the piece highlights the company's raised EPS guidance, margin-expansion targets, and capital-return program, all of which point to a potentially re-rated growth story.
Alcon announced the launch of UNITY M, a premium ophthalmic microscope designed to deliver precise control, according to a Business Wire release.
Why it matters — A new premium product launch reflects Alcon's continued investment in expanding and refreshing its ophthalmic surgical equipment portfolio.
Alcon announced it has priced a EUR 500 million senior notes offering. The announcement was made from Geneva via Business Wire.
Why it matters — The senior notes offering represents a significant capital markets move for Alcon, which ALC watchers would track as a funding and financing development.
Alcon reported strong core operating profit, up 17% excluding a one-time non-cash $402 million charge, and raised its full-year 2026 profit forecast for the second consecutive quarter. A discounted cash flow valuation indicates the stock is trading close to its intrinsic value.
Why it matters — Alcon watchers would note the company's continued strengthening of its profitability outlook, as it upgraded its 2026 profit forecast for the second straight quarter.
The 26 Wall Street analysts covering Alcon AG have a median 12-month price target of $86, with estimates ranging from $62 to $103. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 26 analysts covering Alcon AG, 20 rate it a Buy, 5 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Alcon AG 69 out of 100 across roughly 4,600 US stocks as at 8 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Sept 2026, Alcon AG ranks 69 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (95 of 100).
No one can know that. What the data says: the median 12-month target from 26 analysts implies +25.7% from the last close, and Ticker Nerd's factor model ranks Alcon AG 69 out of 100 as at 8 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Alcon AG publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ALC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $62 to $103 over the next 12 months.
Alcon AG returned -12.8% over the 12 months to 9 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Alcon Inc. is a global eye care company focused on products and technologies that support vision health across surgical and everyday care settings.
The most recent item we track (Zacks Investment Research, 4 Sept 2026): "Is it a Prudent Move to Retain ALC Stock in Your Portfolio Now?". Zacks Investment Research published an analysis of Alcon (ALC), noting that its acquisitions, partnerships, and new product launches support growth while tariffs and intense competition remain key risks.
Alcon Inc. is a global eye care company focused on products and technologies that support vision health across surgical and everyday care settings. Alcon Inc. develops, manufactures, and markets a broad portfolio for cataract surgery, vitreoretinal procedures, glaucoma care, refractive surgery, contact lenses, lens care, and other ocular health needs. Its Surgical business provides implantable products, surgical equipment, diagnostics, and consumables used by ophthalmologists in hospitals and specialty clinics. Its Vision Care business includes daily disposable and reusable contact lenses, color-enhancing lenses, and a range of eye health products for dry eye, allergies, glaucoma support, contact lens care, and redness relief. Headquartered in Geneva, Switzerland, Alcon Inc. serves eye care professionals, medical institutions, and consumers in markets worldwide as a leading provider in ophthalmology and vision care.
CEO Mr. David J. Endicott · 25,000 employees · Switzerland · https://www.alcon.com
